Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: A randomized, placebo-controlled, double-blind, exploratory study

Anesthesia and Analgesia

Volumn 113, Issue 4, 2011, Pages 703-710

  Skolnick, Brett E ^a   Shenouda, Magdy ^b   Khutoryansky, Naum M ^a   Pusateri, Anthony E ^a   Gabriel, Don ^c   Carr, Marcus E ^a  

^a NOVO NORDISK INC   (United States)

^b MDS Inc   (Canada)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; AGITATION; ARTICLE; BLEEDING; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; ECZEMA; ERYTHEMA; EX VIVO STUDY; EXPLORATORY RESEARCH; HEMATOMA; HUMAN; HUMAN EXPERIMENT; LOADING DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PUNCH BIOPSY; RANDOMIZED CONTROLLED TRIAL; REVERSAL REACTION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOELASTOGRAPHY; TREATMENT RESPONSE;

EID: 80053327833     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e318228c690     Document Type: Article

References (39)

1. The CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-39
2. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20 (Pubitemid 35340537)
3. NovoSeven RT Prescribing Information. Princeton, NJ: Novo Nordisk Inc., 2010
4. Altman R, Scazziota A, de Lourdes HM, Gonzalez C. Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. J Thromb Haemost 2006;4:2022-7 (Pubitemid 44226784)
5. Cherfan A, Arabi Y, Al Askar A, Al Shimemeri A. Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. Pharmacotherapy 2007;27:755-9 (Pubitemid 46700968)
6. Hyllner M, Houltz E, Jeppsson A. Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. Eur J Cardiothorac Surg 2005;28:254-8 (Pubitemid 41020693)
7. Loertzer H, Soukup J, Fornara P. Recombinant factor VIIa reduces bleeding risk in patients on platelet aggregation inhibitors immediately prior to renal transplantation: a retrospective analysis. Urol Int 2007;78:135-9 (Pubitemid 46239133)
8. Pfau G, Schilling T, Kozian A, Huth C, Schneemilch CE, Heim MU. A single dose of recombinant activated factor VII (NovoSeven) did not impair the function of the coronary artery bypass grafts: successful treatment of critical bleeding after cardiac surgery in two cases. Transfus Med Hemother 2007;34:204-7 (Pubitemid 46883386)
9. von Heymann C, Schoenfeld H, Sander M, Ziemer S, Grubitzsch H, Spies C. Clopidogrel-related refractory bleeding after coronary artery bypass graft surgery: a rationale for the use of coagulation factor concentrates? Heart Surg Forum 2005;8: E39-41 (Pubitemid 44795274)
10. Diness V, Bregengaard C, Erhardtsen E, Hedner U. Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model. Thromb Res 1992;67:233-41
11. Fattorutto M, Tourreau-Pham S, Mazoyer E, Bonnin P, Raphael M, Morin F, Cupa M, Samama CM. Recombinant activated factor VII decreases bleeding without increasing arterial thrombosis in rabbits. Can J Anaesth 2004;51:672-9 (Pubitemid 39419639)
12. Hindy-Francois C, Bachelot-Loza C, Le Bonniec B, Grelac F, Dizier B, Godier A, Emmerich J, Gaussem P, Samama CM. Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel. Thromb Haemost 2010;104:823-30
13. Lauritzen B, Tranholm M, Ezban M. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. J Thromb Haemost 2009;7:651-7
14. Hyllner M, Houltz E, Jeppsson A. Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. Eur J Cardiothorac Surg 2005;28:254-8 (Pubitemid 41020693)
15. Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood 2010;116:693-701
16. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique 2011;15:124-9
17. Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, Mahmud E, Atar D, Serebruany V. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007;119:277-84 (Pubitemid 44918092)
18. Price MJ, Coleman JL, Steinhubl SR, Wong GB, Cannon CP, Teirstein PS. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol 2006;98:681-4 (Pubitemid 44233472)
19. Takamiya O, Sakata M. Ex vivo coagulation test on tissue factor-expressing cells with a calibrated automated thrombogram. Lab Hematol 2008;14:39-44
20. Young G, Ebbesen LS, Viuff D, Di PJ, Konkle BA, Negrier C, Pasi J, Ingerslev J. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis 2008;19:276-82 (Pubitemid 351670411)
21. McCullagh P, Nelder J. Generalized Linear Models. London: Chapman and Hall, 1996
22. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Banuelos C, Hernandez-Antolin R, Escaned J, Moreno R, Alfonso F, Macaya C. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004;25:1903-10 (Pubitemid 39452607)
23. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005;46:1827-32 (Pubitemid 41579803)
24. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Buttner HJ, Neumann FJ. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560-4 (Pubitemid 40740853)
25. Barsky AA, Arora RR. Clopidogrel resistance: myth or reality? J Cardiovasc Pharmacol Ther 2006;11:47-53
26. Lee DH, Arat A, Morsi H, Shaltoni H, Harris JR, Mawad ME. Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a singlecenter experience. AJNR Am J Neuroradiol 2008;29:1389-94
27. Prabhakaran S, Wells KR, Lee VH, Flaherty CA, Lopes DK. Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 2008;29:281-5 (Pubitemid 351287881)
28. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-51 (Pubitemid 40094733)
29. Feher G, Koltai K, Alkonyi B, Papp E, Keszthelyi Z, Kesmarky G, Toth K. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol 2007;120:188-92 (Pubitemid 47042251)
30. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Macaya C. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006;55:780-4 (Pubitemid 43343236)
31. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5
32. Wiviott SD. Clopidogrel response variability, resistance, or both? Am J Cardiol 2006;98:18N-24N
33. Savage B, Cattaneo M, Ruggeri ZM. Mechanisms of platelet aggregation. Curr Opin Hematol 2001;8:270-6 (Pubitemid 32826497)
34. Varon D, Spectre G. Antiplatelet agents. Hematol Am Soc Hematol Educ Program 2009;2009:267-72
35. Willoughby ML, Allington MJ. The rate of blood loss from skin punctures during the Ivy bleeding time test. J Clin Pathol 1961;14:381-4
36. Kumar R, Ansell JE, Canoso RT, Deykin D. Clinical trial of a new bleeding-time device. Am J Clin Pathol 1978;70:642-5 (Pubitemid 9047260)
37. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005;112:2946-50 (Pubitemid 41612296)
38. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, Slama M, Milleron O, Collet JP, Henry P, Beygui F, Drouet L. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) Trial. J Am Coll Cardiol 2006;48:931-8 (Pubitemid 44292463)
39. Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost 2008;100: 557-62